REGENXBIO Inc.

NasdaqGS:RGNX Stock Report

Market Cap: US$399.8m

REGENXBIO Management

Management criteria checks 2/4

REGENXBIO's CEO is Curran Simpson, appointed in Jul 2024, has a tenure of less than a year. total yearly compensation is $2.95M, comprised of 17.4% salary and 82.6% bonuses, including company stock and options. directly owns 0.073% of the company’s shares, worth $291.87K. The average tenure of the management team and the board of directors is 6.5 years and 7.6 years respectively.

Key information

Curran Simpson

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage17.4%
CEO tenureless than a year
CEO ownership0.07%
Management average tenure6.5yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 15

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07
Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Dec 21
There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Nov 09
We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Curran Simpson's remuneration changed compared to REGENXBIO's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$239m

Jun 30 2024n/an/a

-US$241m

Mar 31 2024n/an/a

-US$260m

Dec 31 2023US$3mUS$513k

-US$263m

Sep 30 2023n/an/a

-US$261m

Jun 30 2023n/an/a

-US$274m

Mar 31 2023n/an/a

-US$270m

Dec 31 2022US$2mUS$475k

-US$280m

Sep 30 2022n/an/a

US$74m

Jun 30 2022n/an/a

US$91m

Mar 31 2022n/an/a

US$101m

Dec 31 2021US$3mUS$448k

US$128m

Sep 30 2021n/an/a

-US$212m

Jun 30 2021n/an/a

-US$145m

Mar 31 2021n/an/a

-US$121m

Dec 31 2020US$2mUS$428k

-US$111m

Sep 30 2020n/an/a

-US$91m

Jun 30 2020n/an/a

-US$135m

Mar 31 2020n/an/a

-US$103m

Dec 31 2019US$2mUS$382k

-US$95m

Sep 30 2019n/an/a

-US$64m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$2mUS$371k

US$100m

Compensation vs Market: Curran's total compensation ($USD2.95M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Curran's compensation has increased whilst the company is unprofitable.

CEO

Curran Simpson (62 yo)

less than a year

Tenure

US$2,950,002

Compensation

Mr. Curran M. Simpson, M.S., had been the Chief Operating Officer at REGENXBIO Inc. since January 2023 until July 01, 2024 and served as its Executive Vice President until July 01, 2024 and serves as its P...

Leadership Team

NamePositionTenureCompensationOwnership
Curran Simpson
Presidentless than a yearUS$2.95m0.073%
$ 291.9k
Olivier Danos
Executive VP & Chief Scientific Officer7.9yrsUS$2.99m0.099%
$ 396.2k
Stephen Pakola
Executive VP & Chief Medical Officer5.8yrsUS$3.31m0.044%
$ 175.5k
Mitchell Chan
Executive VP & CFOless than a yearno datano data
Patrick Christmas
Executive VP & Chief Legal Officer8.5yrsUS$3.44m0.086%
$ 342.7k
Shiva Fritsch
Chief Communications & People Officer7.3yrsno datano data
Ram Palanki
Executive VP of Commercial Strategy & Operations6.5yrsno datano data

6.5yrs

Average Tenure

54yo

Average Age

Experienced Management: RGNX's management team is seasoned and experienced (6.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Curran Simpson
Presidentless than a yearUS$2.95m0.073%
$ 291.9k
David Stump
Independent Director9.3yrsUS$339.98k0.0061%
$ 24.3k
George Migausky
Independent Director3.4yrsUS$339.98k0.0061%
$ 24.3k
Argeris Karabelas
Independent Director9.8yrsUS$352.48k0.013%
$ 52.4k
Inder Verma
Member of Scientific Advisorno datano datano data
Allan Fox
Director16yrsUS$354.98k6.39%
$ 25.5m
Judith Swain
Member of Scientific Advisorno datano datano data
Alexandra Glucksmann
Independent Director6.8yrsUS$327.48k0.0061%
$ 24.3k
Daniel Tassé
Lead Independent Director8.5yrsUS$334.98k0.0061%
$ 24.3k
Jean Bennett
Independent Director3.4yrsUS$324.98k0.0061%
$ 24.3k
Kenneth Mills
Chairman15.9yrsUS$5.92m0.63%
$ 2.5m
Jennifer Zachary
Independent Director2.7yrsUS$329.98k0.0040%
$ 16.2k

7.6yrs

Average Tenure

69.5yo

Average Age

Experienced Board: RGNX's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 10:26
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

REGENXBIO Inc. is covered by 20 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Alec StranahanBofA Global Research